Vascular Ultrasound in Percutaneous Closure Devices: Subanalysis of the UNIVERSAL-Trial

Analysis of percutaneous closure device placement when choosing an ultrasound-guided vs. a fluoroscopy-guided femoral approach.


Transradial access is the access of choice in percutaneous coronary interventions, with a demonstrated benefit in mortality and bleeding when compared with transfemoral access. The latter, however, is still the access of choice in cases where large caliber introducers are used or in cases where the transradial approach is not available.

Ecografía vascular en dispositivos de cierre percutáneo: Subanálisis del UNIVERSAL-Trial

Several studies have shown that the use of percutaneous closure devices (PCD) has reduced the time to hemostasis and time to ambulation when using the transfemoral approach.

The objective of this prespecified subanalysis of the UNIVERSAL-Trial was to explore the association between vascular ultrasound (US)-guided puncture and the use of PCD in terms of bleeding and vascular complications.

This was a multicenter, open-design, randomized study, which compared US-guided puncture vs. fluoroscopy-guided puncture for PCD placement in coronary procedures. Patients <18 years of age with coronary syndrome with ST elevation or absence of palpable femoral pulse were excluded. The subjects were randomized 1:1 and US was used exclusively for the puncture, not to guide PCD placement.

The primary endpoint (PEP) was a composite of BARC type 2, 3, or 5 bleeding, or a major vascular complication (femoral pseudoaneurysm, arteriovenous fistula, retroperitoneal bleeding, hematoma >5 cm in diameter, or limb ischemia requiring intervention within 30 days).

Read also: ACC 2023 | COORDINATE-DIABETES.

A total of 621 patients were randomized and followed-up. Out of all patients, 54.7% of patients in the US group and 51% in the fluoroscopy-guided puncture group received a PCD. 

Mean age was 70 years; 25.6% of subjects were female, 54.2% had a previous AMI, 39.9% had diabetes, and 54% had undergone a previous myocardial revascularization surgery. A 6Fr introducer sheath was used in 74.1% of cases; in 82% of all US-guided punctures the ANGIO-SEAL device was used. Successful common femoral cannulation was observed in 87.6% of all US-guided punctures compared with 90.4% in all non-guided punctures.

In patients who received a PCD, the US-guided approach showed a 66% reduction in the PEP (odds ratio [OR] 0.44; 95% confidence interval [CI]: 0.23-0.82), whereas in patients who did not receive a PCD, there were no significant differences (OR: 1.76; 95% CI: 0.80-4.03). The subgroup of patients in which the ANGIO-SEAL device was used experienced significantly fewer complications (OR: 0.33; 95% CI: 0.15-0.71), an effect not seen with the ProGlide device (OR: 0.74; 95% CI: 0.14-3.31).

Read also: Mechanical Aspiration in ST Elevation ACS.

The benefit of ultrasound use was at the expense of vascular complications (OR: 0.28; 95% CI: 0.10-0.71), with no differences observed in patients where PCDs were not used. There were no differences in bleeding for either group. Hematomas <5cm were 3 times more frequent when the PCD was placed without ultrasound guidance.

Conclusions

When deciding to place a percutaneous closure device in coronary procedures, ultrasound guidance of the transfemoral puncture significantly decreased vascular complications, with no changes in BARC 2, 3, or 5 type bleeding. Since this study was conducted in a subgroup, this hypothesis should be considered regarding the routine use of US for this type of device.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Ultrasound-guided femoral access in patients with vascular closure devices: a prespecified analysis of the randomised UNIVERSAL trial.

Reference: d’Entremont MA, Alrashidi S, Alansari O, et al. Ultrasound-guided femoral access in patients with vascular closure devices: a prespecified analysis of the randomised UNIVERSAL trial [published online ahead of print, 2023 Feb 25]. EuroIntervention. 2023;EIJ-D-22-01130. doi:10.4244/EIJ-D-22-01130.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....